Medtronic plc Stock
€81.31
Your prediction
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Not a member yet? Sign up for free!
Financial data and news for Medtronic
sharewise wants to provide you with the best news and tools for Medtronic, so we directly link to the best financial data sources.
Financials
News
The Smartest Dividend Stocks to Buy With $10,000 Right Now
How should you invest if you've just received a quick windfall? Say $10,000 or even $100,000. The stock market is near all-time highs, so an aggressive investment stance will likely expose you to a
3 Reasons Medtronic's Stock Can Continue Rallying Higher
Medtronic (NYSE: MDT) hasn't been a terribly hot stock to own in recent years. Since 2021, its shares have declined by more than 20%. But recently, investors do appear to have been giving the stock
Billionaire Ray Dalio's Former Hedge Fund Is Buying These 3 Top Dividend Stocks. Should You?
Savvy investors often look to billionaire portfolios for quality dividend stock ideas. Ray Dalio, founder of Bridgewater Associates, has a stellar reputation for spotting promising investments
Is Medtronic Stock a Buy?
Medical device giant Medtronic (NYSE: MDT) has been somewhat of a stock market laggard over the past five years, partly due to pandemic-related disruptions. Even beyond this global issue, the
This Is Great News for Medtronic, but Is It Time to Buy the Stock?
Medtronic (NYSE: MDT) posted first-quarter earnings (for the period ended on June 30) that exceeded the average of Wall Street estimates. The results were strong enough for the medical technologies
Medtronic (MDT) Q1 2025 Earnings Call Transcript
Medtronic (NYSE: MDT)Q1 2025 Earnings CallAug 20, 2024, 8:00 a.m. ET
Ryan Weispfenning -- Vice President and Head, Investor Relations
Source Fool.com
2 Dividend Stocks to Buy and Never Sell
Every corporation will face challenges and setbacks -- which will sometimes sink its stock price. That's not a good reason for long-term investors to jump ship unless, of course, there's a
How Much Will Medtronic Pay Out in Dividends This Year?
Medtronic (NYSE: MDT), a beast of a medical-device company, has caught the eye of more than a few income investors. It has enacted dividend raises at least once annually for a hard-to-beat 47 years
3 High-Yield Dividend Stocks to Buy in the 2nd Half of 2024 and Hold at Least a Decade
The market's been on a bull run, but most of the gains have been confined to a handful of tech stocks at the top. There are still plenty of high-yield dividend stocks that haven't gained as much
2 Healthcare Stocks to Buy Hand Over Fist This Month
Healthcare never sleeps. There is always demand for medical services, regardless of the state of the economy. Companies that offer these necessary goods and are innovative enough to keep up with the
Got $200? 2 Healthcare Stocks to Buy and Hold Forever.
Few industries are more essential than healthcare. That makes it an excellent place to look for stocks that can perform well over extended periods since the basic services they offer are unlikely to
Medtronic Raised Its Dividend for a 47th Straight Year, But Here's Why It Isn't a Great Dividend Growth Stock
Dividend growth stocks can make for excellent long-term investments. Their ongoing rate increases allow investors to generate more in dividend income than if they were to just invest in a stale
Is Medtronic Stock a Buy?
Medtronic (NYSE: MDT) is a top healthcare company and a leading maker of medical devices. At a market cap of more than $100 billion, the business has soundly established itself in the industry. It
Medtronic Stock Is a Sell, According to 1 Wall Street Analyst
One week ago, medical device maker Medtronic (NYSE: MDT) surpassed Wall Street's sales and earnings targets. Despite the earnings beat, and despite giving guidance that mostly matched analysts'
Medtronic Stock Could Soar 29%, According to a Wall Street Analyst. Is the Dividend Champion a Buy Now?
Shares of Medtronic (NYSE: MDT) responded poorly to the company's latest quarterly results announcement. The market knocked the stock about 5% lower on May 23, but some analysts who follow the
Medtronic (MDT) Q4 2024 Earnings Call Transcript
Medtronic (NYSE: MDT)Q4 2024 Earnings CallMay 23, 2024, 8:00 a.m. ET
Ryan Weispfenning
Source Fool.com
Why Medtronic Stock Slumped Today
Medtronic (NYSE: MDT) stock slipped 2.8% through 10:15 a.m. ET this morning despite beating earnings forecasts in its fiscal Q4 2024 earnings report.
Heading into earnings, analysts had the medical
These Dividend Stocks Are an Investor's Best Friend
Dividend stocks tend to struggle in high-interest-rate environments. The core reason is investors have an abundance of low-risk, high-yield income options when interest rates spike.
Conversely, fund
Medtronic Stock: Buy, Sell, or Hold?
Medtronic (NYSE: MDT) is a leading global medical device company with a massive presence that spans more than 150 countries. Its products assist patients with over 70 different health conditions
Got $200? 2 Healthcare Stocks to Buy and Hold Forever.
There are plenty of things to buy with $200. But what about investing in a company that can grow your capital for years? Though some people believe they need millions, or at least thousands, to
Medtronic Stock: Growth On Rise of the Cardiovascular Machines
Medtronic plc (NYSE: MDT) is a leading global medical device maker in the medical sector. Its innovative and critical medical device portfolio addresses chronic diseases an aging population
Diabetes and Neuro Products Ignite Medtronic’s Q1 Earnings Rally
Shares of medical device manufacturer Medtronic PLC (NYSE: MDT) are down about 35% from their highs of roughly three years ago, but promising results from the company's first quarter of fiscal
Medtronic Dips: Is Now the Time to Buy?
Shares of Medtronic (NYSE: MDT) are falling following its FQ4 release and guidance, opening up a potential buying opportunity. The question is whether its value, yield, balance sheet and cash flow